Human OSMR-GPL fusion Protein

Cat. No. OSG-HM101

Description

Source	Recombinant Human OSMR-GPL fusion Protein is expressed from HEK293 with His tag at the C-terminus.
	It contains Met1-Ala428 (OSMR) and Leu21-Glu225 (GPL).
Accession	Q99650-1(OSMR)&Q8NI17-1(GPL)
Molecular Weight	The protein has a predicted MW of 75.84 kDa. Due to glycosylation, the protein migrates to 110-140 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE

Formulation and Storage

Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

OSMR involvement, together with Gp130-like receptor (GPL), also known as IL-31R, in the formation of a functional IL-31 receptor complex. OSMR-GPL fusion protein was designed to contain the domains of OSMR and GPL required for high affinity IL-31 binding.

Assay Data

Bis-Tris PAGE



Human OSMR-GPL fusion Protein on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Human OSMR-GPL fusion Protein

Cat. No. OSG-HM101

Assay Data



Immobilized Human OSMR-GPL fusion Protein, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-OSMR Antibody, hFc Tag with the EC50 of 5.4ng/ml determined by ELISA.